


Active Filter(s):
Details:
Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Lead Product(s): Lanthanum Carbonate
Therapeutic Area: Nephrology Product Name: Renazorb
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022